PTGS2 and colorectal cancer: As mentioned previously, COX-2 and prostaglandin E2 (PGE2) overexpression has been shown to upregulate tumor-promoting cytokines and growth factors, and COX-2 inhibition with celecoxib can augment tumor regression with immune checkpoint blockade in colorectal cancer xenograft models [22, 29].